Prevention of contrast media nephrotoxicity - the story so far

被引:71
作者
Morcos, SK [1 ]
机构
[1] No Gen Hosp, Dept Diagnost Imaging, Sheffield Teaching Hosp NHS Trust, Sheffield S5 7AU, S Yorkshire, England
关键词
contrast media; nephrotoxicity; endothelins; adenosine; acetylcysteine; haemofiltration;
D O I
10.1016/j.crad.2003.11.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];
摘要
Contrast media nephrotoxicity (CMN) in patients with pre-existing renal impairment remains a clinically significant problem. The first step to reduce the chance of CMN is to identify patients at risk through the use of screening questionnaires and renal function measurement. Patients at risk requiring injection of contrast medium (CM) because of important clinical indications should receive a small dose of either nonionic iso-osmolar dimeric or non-ionic low osmolar monomeric CM and hydration. Intravenous infusion (1 ml/kg body weight/h) of 0.9% saline starting 4 h before CM injection and continuing for at least 12 h afterwards is effective in reducing the incidence of CMN. Prophylactic haemodialysis does not lower the risk of this complication. The value of pharmacological manipulation with renal vasodilators (calcium channel blockers, dopamine, atrial. natriuretic peptide, fenoldopam (selective dopamine-1 receptor agonist), prostaglandin El, non-selective adenosine receptors antagonist (theophylline), non-selective endothelin receptor antagonist or the antioxidant acetylcysteine has not been fully proven. However, haemofiltration for several hours before and after contrast medium injection offers good protection against CMN in patients with advanced renal disease. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:381 / 389
页数:9
相关论文
共 46 条
[1]
Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy [J].
Allaqaband, S ;
Tumuluri, R ;
Malik, AM ;
Gupta, A ;
Volkert, P ;
Shalev, Y ;
Bajwa, TK .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 57 (03) :279-283
[2]
Role of adenosine in the renal responses to contrast medium [J].
Arakawa, K ;
Suzuki, H ;
Naitoh, M ;
Matsumoto, A ;
Hayashi, K ;
Matsuda, H ;
Ichihara, A ;
Kubota, E ;
Saruta, T .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1199-1206
[3]
Nephrotoxic effects in high-risk patients undergoing angiography. [J].
Aspelin, P ;
Aubry, P ;
Fransson, S ;
Strasser, R ;
Willenbrock, R ;
Berg, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :491-499
[4]
Acetylcysteine for prevention of contrast nephropathy:: meta-analysis [J].
Birck, R ;
Krzossok, S ;
Markowetz, F ;
Schnülle, P ;
van der Woude, FJ ;
Braun, C .
LANCET, 2003, 362 (9384) :598-603
[5]
In-stent restenosis in small coronary arteries - Impact of strut thickness [J].
Briguori, C ;
Sarais, C ;
Pagnotta, P ;
Liistro, F ;
Montorfano, M ;
Chieffo, A ;
Sgura, F ;
Corvaja, N ;
Albiero, R ;
Stankovic, G ;
Toutoutzas, C ;
Bonizzoni, E ;
Di Mario, C ;
Colombo, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (03) :403-409
[6]
Carraro M, 1996, NEPHROL DIAL TRANSPL, V11, P444
[7]
Comparison of iodixanol and iohexol in renal impairment [J].
Chalmers, N ;
Jackson, RW .
BRITISH JOURNAL OF RADIOLOGY, 1999, 72 (859) :701-703
[8]
Choyke P L, 1998, Tech Urol, V4, P65
[9]
DOSING OF CONTRAST MATERIAL TO PREVENT CONTRAST NEPHROPATHY IN PATIENTS WITH RENAL-DISEASE [J].
CIGARROA, RG ;
LANGE, RA ;
WILLIAMS, RH ;
HILLIS, LD .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (06) :649-652
[10]
DEHNARTS T, 1998, NEPHROL DIAL TRANSPL, V13, P358